Bioverativ: More Than Just A Hemophilia Company
Executive Summary
The blood disease specialist, to be acquired by Sanofi, is best known for its two marketed hemophilia drugs, but Bioverativ spent 2017 working on business development and diversifying beyond hemophilia. Scrip talked to CEO John Cox about the pipeline just before the merger was announced.
You may also be interested in...
Biopharma Quarterly Dealmaking Statistics, Q1 2018
Biopharma financing started the year solidly with $16.6 billion in total deal value, a 14% increase over the previous quarter. Q1 2018 biopharma merger and acquisition deal value, led by Cigna's $67 billion buy of Express Scripts, topped even the previous all-time-high set in Q4 2107, while alliances totaled $30.7 billion and featured big oncology and neurology partnerships.
Deal Watch: Roche Goes All-In On Real-World Data With Flatiron Acquisition
Already a significant investor in the health care technology firm, buyout will give Roche access to substantial real-world cancer development data. Astellas acquires stem cell-focused Universal Cells.
Sanofi Builds Blood Disorder Specialty With Bioverativ Buy
The French drug maker is making a big splash into blood disorders with the $11.6bn acquisition of hemophilia specialist Bioverativ. Eloctate and Alprolix are young and growing brands, but the competition in hemophilia is fierce, which means Bioverativ's pipeline will also need to deliver to justify the premium price.